Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent
摘要:
The search for novel androgen receptor (AR) down-regulating agents by catalyst HipHop pharmacophore modeling led to the discovery of some lead molecules. Unexpectedly, the effect of these leads on human prostate cancer LNCaP cell viability did not correlate with the ability of the compounds to cause down-regulation of AR protein expression. Through rational synthetic optimization of the lead compound (BTB01434), we have discovered a series of novel substituted diaryl molecules as potent anti-prostate cancer agents. Some compounds (1-6) were shown to be extremely potent inhibitors of LNCaP cell viability with GI(50) values in the nanomolar range (1.45-83 nM). The most potent compound (4-methylphenyl)[(4-methylphenyl) sulfonyl] amine (5) with a GI(50) value of 1.45 nM is 27,000 times more potent than our lead compound BTB01434 (GI(50) = 39.8 mu M). In addition, some of the compounds exhibited modest anti-androgenic activities and one was also a potent inhibitor (GI(50) = 850 nM) of PC-3 (AR-null) cell growth. A clear structure-activity relationship (SAR) has been established for activity against LNCaP cells, where potent molecules possess two substituted/unsubstituted aromatic rings connected through a sulfonamide linker. These novel compounds are strong candidates for development for the treatment of hormone-sensitive and importantly hormone-refractory prostate cancers in humans. (C) 2008 Elsevier Ltd. All rights reserved.
ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND
申请人:Njar Vincent C. O.
公开号:US20100113600A1
公开(公告)日:2010-05-06
A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer.
[EN] ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND<br/>[FR] AGENTS ANTI-CANCER ET COMPOSÉ INHIBANT L'ACTIVITÉ ANDROGÈNE
申请人:UNIV MARYLAND
公开号:WO2008076918A2
公开(公告)日:2008-06-26
(EN) A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer.(FR) L'invention concerne un modèle 3D qualitatif de pharmacophore (un modèle fondé sur une fonctionnalité courante ou un algorithme Catalyst HipHop) développé à partir d'agents rétro-régulateurs du récepteur androgène (ARDA) naturels. Le modèle 3D de pharmacophore est utilisé en tant que modèle pour le criblage virtuel de composés dans le but d'identifier de nouveaux ARDA. L'invention concerne également des composés ARDA et des composés qui inhibent fortement la croissance des cellules LNCaP de la prostate humaine. Les composés peuvent être utilisés dans des compositions et des procédés pour inhiber la prolifération cellulaire d'un cancer et dans des procédés de prévention ou de traitement du cancer, notamment du cancer de la prostate.
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent
作者:Puranik Purushottamachar、Aakanksha Khandelwal、Tadas S. Vasaitis、Robert D. Bruno、Lalji K. Gediya、Vincent C.O. Njar
DOI:10.1016/j.bmc.2008.02.031
日期:2008.4.1
The search for novel androgen receptor (AR) down-regulating agents by catalyst HipHop pharmacophore modeling led to the discovery of some lead molecules. Unexpectedly, the effect of these leads on human prostate cancer LNCaP cell viability did not correlate with the ability of the compounds to cause down-regulation of AR protein expression. Through rational synthetic optimization of the lead compound (BTB01434), we have discovered a series of novel substituted diaryl molecules as potent anti-prostate cancer agents. Some compounds (1-6) were shown to be extremely potent inhibitors of LNCaP cell viability with GI(50) values in the nanomolar range (1.45-83 nM). The most potent compound (4-methylphenyl)[(4-methylphenyl) sulfonyl] amine (5) with a GI(50) value of 1.45 nM is 27,000 times more potent than our lead compound BTB01434 (GI(50) = 39.8 mu M). In addition, some of the compounds exhibited modest anti-androgenic activities and one was also a potent inhibitor (GI(50) = 850 nM) of PC-3 (AR-null) cell growth. A clear structure-activity relationship (SAR) has been established for activity against LNCaP cells, where potent molecules possess two substituted/unsubstituted aromatic rings connected through a sulfonamide linker. These novel compounds are strong candidates for development for the treatment of hormone-sensitive and importantly hormone-refractory prostate cancers in humans. (C) 2008 Elsevier Ltd. All rights reserved.
Tandem Reduction, Ammonolysis, Condensation, and Deamination Reaction for Synthesis of Benzothiadiazines and 1-(Phenylsulfonyl)-1<i>H</i>-benzimidazoles
A novel route for a SnCl2-promoted tandem reduction, ammonolysis, condensation, and deamination reaction which uses nitrile and 2-nitro-N-phenylbenzenesulfonamide/N-(2-nitrophenyl)benzenesulfonamide to synthesize derivatives of benzothiadiazine/1-(phenylsulfonyl)-1H-benzimidazole has been developed. The method features convenient operation and good functional group tolerance. In addition, it employs
SnCl 2促进串联还原、氨解、缩合和脱氨反应的新路线以腈和2-硝基-N-苯基苯磺酰胺/ N- (2-硝基苯基)苯磺酰胺合成苯并噻二嗪/1-(苯磺酰基)衍生物开发了-1H-苯并咪唑。该方法操作方便,官能团耐受性好。此外,它采用不敏感且廉价的 SnCl 2 / i -PrOH 作为反应试剂,为合成重要的药学靶标提供了直接途径。